UNSPSC 51283603: Rifapentine

This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XJM390A33U. European Medicines Agency schedules Rifapentine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10311MIG. Rifapentine generally arises in the molecular formula C47H64N4O12.

The term RIFAPENTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 34, no. 10 1980, list 20.) RIFAPENTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifapentine under HS 29419000 and SITC 54139. As of Q4 2014, RIFAPENTINE remains the US FDA Preferred Term for this commodity. Rifapentine bears US NLM identifiers UMLS ID C0073372 and NCI Concept Code C66516.

UNSPSC 51283603 Rifapentine is a Commodity code for a specific tuberculosis treatment pharmaceutical, yet the recent state and local opportunities tagged under it do not reflect procurement of rifapentine itself. Instead, the opportunities show state and local health agencies acquiring other pharmaceutical products—antibiotics and naloxone—through piggyback contracts and competitive bids tied to public health emergencies and community health initiatives. The work being solicited includes bulk pharmaceutical supply through cooperative purchasing vehicles and direct county procurement, with quarterly or as-needed delivery to health department facilities and community health centers. Issuing bodies include state departments of public health and county health authorities, typically managing these procurements through invitation-for-bid or piggyback mechanisms tied to established pharmaceutical consortiums.

The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for doxycycline hyclate and ciprofloxacin hydrochloride, valued at $2,999,999.11 over the contract life with renewal options. Seminole County, Florida released an IFB on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2026. Geographic activity is concentrated in the Southeast and Midwest, though the code's taxonomy mismatch with actual recent opportunities suggests limited direct rifapentine procurement visibility in recent state and local notices.